Y-mAbs Therapeutics (NASDAQ:YMAB) just reported results for the second quarter of 2024.
- Y-mAbs Therapeutics reported earnings per share of -21 cents. This was below the analyst estimate for EPS of -13 cents.
- The company reported revenue of $22.80 million.
- This was 0.96% worse than the analyst estimate for revenue of $23.02 million.